Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer

Inclusion Criteria

• •All patients with a diagnosis of complex atypical hyperplasia or endometrial biopsy within three months of study enrollment OR patients with a diagnosis of grade 1 endometrioid endometrial carcinoma on endometrial biopsy within three months of study enrollment in the presence of one or more of the following: 1)desire for future fertility 2)morbid obesity (body mass index \> 40) 3)multiple co-morbidities (ASA Class 3 or 4)
• •Women of any racial or ethnic group.
• •Ability to comply with endometrial biopsies every 3 months.
• •Willing and able to sign informed consent.
• •Age greater than 18 years.
• •Diagnosis of grade 2 endometrioid endometrial carcinoma or higher on endometrial biopsy or on dilation and curettage specimen.
• •Evidence of extrauterine spread of disease on imaging or during surgical evaluation.
• •Congenital or acquired uterine anomaly which distorts the uterine cavity.
• •Acute pelvic inflammatory disease.
• •Acute liver disease or previously diagnosed liver tumor (benign or malignant).
• •Conditions associated with increased susceptibility to infections with microorganisms. Such conditions include, but are not limited to, AIDS, leukemia and IV drug abuse.
• •Genital actinomycosis.
• •Current carcinoma of the breast.
• •Current pregnancy.
• •Breastfeeding mothers.